Experimental pill fights COVID-19, drug-maker Merck claims
Global News
Several other companies, including Pfizer and Roche, are studying similar drugs that could report results in the coming weeks and months.
Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.
If cleared, Merck’s drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.
Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease.
Among patients taking molnupiravir, 7.3 per cent were either hospitalized or died at the end of 30 days, compared with 14.1 per cent of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck. The results were released by the company and have not been peer reviewed. Merck said it plans to present them at a future medical meeting.
An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong. Company executives said they are in discussions with the Food and Drug Administration and plan submit the data for review in coming days.
“It exceeded what I thought the drug might be able to do in this clinical trial,” said Dr. Dean Li, vice president of Merck research. “When you see a 50 per cent reduction in hospitalization or death that’s a substantial clinical impact.”
Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems.
Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.
The ceasefire's first phase is set to end in two weeks and the second phase has yet to be negotiated, though talks were meant to begin two weeks ago.
The proposal did not offer any specific security guarantees in return, according to one current and one former senior Ukrainian official familiar with the talks.
European leaders are reeling after Trump's decision to upend years of U.S. policy by holding talks with Russian President Vladimir Putin in hopes of ending the Russia-Ukraine war.
Sources told Reuters that the United States had sent a document to European capitals asking questions that include possible future troop contributions.
It is the sixth swap since the ceasefire took effect on Jan. 19. Before Saturday, 21 hostages and over 730 Palestinian prisoners were freed.
The latest fighting is part of a major escalation of a conflict over power, identity and resources dating back to the 1990s Rwandan genocide.
The red and white has been a symbol of national pride for many decades, and in the wake of Donald Trump's anti-Canadian rhetoric, a sense of patriotism is sweeping the country.
U.S. Vice-President JD Vance warned governments that internal threats to democracy are a greater threats than external antagonists like China and Russia.
Alarmed that U.S. security priorities lie elsewhere, a group of European countries has been working on a plan to send troops into Ukraine to enforce any peace settlement.
"There is no talk about strikes on nuclear infrastructure, nuclear energy facilities," Kremlin spokesperson Dmitry Peskov said, denying Russia had any responsibility.
Ukrainians who fled to Canada following Russia's invasion say they feel betrayed by U.S. President Donald Trump's comments on the prospects for peace in Ukraine.
NATO's secretary-general said as the U.S. proceeds on Ukraine peace talks with Russia, the alliance will work to ensure Moscow never tries to attack Ukraine again.
European officials took an exceptionally firm line in public towards Trump's peace overture, saying they and the Ukrainians must be included in any negotiations.